Glatt Pharmaceutical Services, a division of Glatt Air Techniques, Inc., has made several appointments as part of its expansion initiative. Robert Femia, Ph.D. has been named vice president of R&D at Glatt Pharmaceutical Services. Dr. Femia has more than 20 years’ experience in pharmaceutical product and analytical chemistry development. Prior to joining the company, he was the executive vice president of pharmaceutical research at Par Pharmaceuticals where he lead the development of many generic products and the companies first approved NDA for an extended release product. His responsibilities at Glatt will be to manage its growing R&D services to the pharmaceutical industry in addition to Glatt’s internal product development efforts.

Bill Bundenthal has joined the company as vice president of operations. He has more than 20 years of experience in management of manufacturing operations. Prior to joining the company he was vice president of manufacturing operations and facility engineering at Par Pharmaceuticals and held previous positions at Lederle Laboratories and Barr Pharmaceuticals. His responsibilities at Glatt include overseeing the completion of a multi-million dollar facility expansion to increase capacity and capabilities, including organic solvent and modified release processing in both its R&D and commercial manufacturing areas. Mr. Bundenthal will also be responsible for the commercial manufacturing operations, warehousing, and facility engineering.

Both Dr. Femia and Mr. Bundenthal will report to Oliver Mueller, executive vice president, Glatt Pharmaceutical Services.